KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Cash from Financing Activities (2016 - 2026)

Amgen has reported Cash from Financing Activities over the past 18 years, most recently at $1.4 billion for Q1 2026.

  • For Q1 2026, Cash from Financing Activities rose 134.96% year-over-year to $1.4 billion; the TTM value through Mar 2026 reached -$5.3 billion, up 55.0%, while the annual FY2025 figure was -$10.9 billion, 15.34% down from the prior year.
  • Cash from Financing Activities for Q1 2026 was $1.4 billion at Amgen, up from -$1.2 billion in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $21.5 billion in Q1 2023 and troughed at -$4.1 billion in Q1 2025.
  • A 5-year average of -$107.5 million and a median of -$1.4 billion in 2024 define the central range for Cash from Financing Activities.
  • On a YoY basis, Cash from Financing Activities climbed as much as 712.09% in 2023 and fell as far as 226.26% in 2023.
  • Year by year, Cash from Financing Activities stood at -$1.0 billion in 2022, then soared by 362.54% to $2.8 billion in 2023, then tumbled by 151.09% to -$1.4 billion in 2024, then rose by 12.86% to -$1.2 billion in 2025, then skyrocketed by 217.13% to $1.4 billion in 2026.
  • Business Quant data shows Cash from Financing Activities for AMGN at $1.4 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$2.9 billion in Q3 2025.